PharmAthene to Present at the 7th Annual BIO Investor Forum in San Francisco

ANNAPOLIS, Md., Oct. 23 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (NYSE:
PIP) a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that David P. Wright,
President and Chief Executive Officer of PharmAthene, will present at the 7th
Annual BIO Investor Forum in San Francisco on Thursday, October 30, 2008 at
11:00 a.m. Pacific Time.

PharmAthene's presentation will be available via webcast on the company's
website at www.pharmathene.com. To access the webcast go to the Investor
Relations page and click on the links News & Events/ Calendar of Events
/PharmAthene at 7th Annual BIO Investor Forum. For assistance contact Stacey
Jurchison at 410-269-2610.

About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its
allies by developing and commercializing medical countermeasures against
biological and chemical weapons. PharmAthene's lead product development
programs include:

-- SparVax(TM) - a second generation recombinant protective antigen (rPA)
anthrax vaccine
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve
agents
-- RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

SOURCE PharmAthene, Inc.

Stacey Jurchison, Director, Corporate Communications of PharmAthene, Inc.,
+1-410-269-2610, Cell +1-410-474-8200, JurchisonS@PharmAthene.com